Beyond its role in therapy, FMT is providing insights into the importance of intestinal microbiota in health and disease
As physicians and scientists, we live in exciting times! Bacteria are no longer viewed solely as pathogens, but also as key partners in the maintenance of health. It is conceivable that altering the microbiota in our gastrointestinal tract may either predispose us to disease or ameliorate conditions we already have. Faecal microbiota transplantation (FMT) has captured the attention of the lay press and professional journals since 1958, when faecal enema was reported to have cured four patients near death from severe Micrococcus pyogenes colitis.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-859.
- 2. Chang J, Antonopoulos D, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435-438.
- 3. Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 761-767.
- 4. Weingarden AR, Dosa PI, DeWinter E, et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS One 2016; 11: e0147210.
- 5. Staley C, Kelly CR, Brandt LJ, et al. Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile Infection following fecal microbiota transplantation. mBio 2016; 7: e01965-16.
- 6. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016; 65: 609-616.
- 7. Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology 2017; 152: 799-811.
- 8. Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust 2017; 207: 166-172.
- 9. Fehrer C, Mensa J. A comparison of current guidelines of five international societies on Clostridium difficile infection management. Infect Dis Ther 2016; 5: 207-230.
- 10. Wang S, Mengque X, Wang W, et al. Adverse events of fecal microbiota transplantation. PLoS One 2016; 11: e0161174.
- 11. Razik R, Osman M, Lieberman A, et al. Faecal microbiota transplantation for Clostridium difficile infection: a multicentre study of non-responders. Med J Aust 2017; 207: 159-160.
No relevant disclosures.